Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series - PubMed (original) (raw)
Clinical Trial
. 2000:11 Suppl 1:137-40.
F Cabanillas, P McLaughlin, T Smith, F Hagemeister, M A Rodríguez, J E Romaguera, A Younes, A H Sarris, H A Preti, W Pugh, M S Lee
Affiliations
- PMID: 10707796
Clinical Trial
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series
A López-Guillermo et al. Ann Oncol. 2000.
Abstract
Background: We have observed that molecular response, as defined by a PCR-negative status during the first year of therapy, along with beta 2-microglobulin (beta 2M), was the most important variable associated with failure-free survival (FFS) in follicular lymphoma (FL). Herein, we present an update of the previously published MDACC series.
Patients and methods: A total of 116 patients (male:female ratio 64:52; median age: 52 years) with indolent FL and BCL-2 rearrangement (at MBR or mcr breakpoints) assessable in peripheral blood (pb) by PCR prior to treatment, and with two or more PCR determinations during the first year, were selected for the present study.
Results: Of the 116 patients, 4 who presented with progression and 1 who died of unrelated causes during the first year were excluded from the landmark analysis. One hundred patients (86%) achieved clinical CR and 80 (69%) achieved a negative PCR status within first year. Median FFS was 6.4 years. Five-year FFS was 73% and 28% for molecular responders and nonresponders, respectively (P = 0.001). In spite of this strikingly higher FFS favoring molecular responders, no clearcut plateau was evident in this group. Molecular response assessed in pb (P = 0.001) and serum beta 2M (P < 0.001) were the most important factors to predict FFS in the multivariate analysis. In the subset of patients with normal beta 2M and molecular CR, there was a trend for a plateau in the FFS curve. No significant difference between the groups has been observed so far in terms of survival.
Conclusions: Molecular response assessed in pb using a PCR technique is, along with beta 2M, the most important factor to predict FFS in FL.
Similar articles
- Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
López-Guillermo A, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. López-Guillermo A, et al. Blood. 1999 May 1;93(9):3081-7. Blood. 1999. PMID: 10216105 - Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T, Jedlicková K, Kriegová E, Jarosová M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K. Papajík T, et al. Neoplasma. 2001;48(6):501-5. Neoplasma. 2001. PMID: 11949845 - Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma.
Montoto S, López-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A, Villamor N, Moreno C, Campo E, Montserrat E. Montoto S, et al. Leuk Lymphoma. 2003 Jan;44(1):71-6. doi: 10.1080/1042819021000050052. Leuk Lymphoma. 2003. PMID: 12691144 - Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Seymour JF, et al. J Clin Oncol. 2003 Jun 1;21(11):2115-22. doi: 10.1200/JCO.2003.07.111. J Clin Oncol. 2003. PMID: 12775737 Review. - Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
Cited by
- Comparing the ability of freshly generated and cryopreserved dendritic cell vaccines to inhibit growth of breast cancer in a mouse model.
Radhakrishnan AK, Sim GC, Cheong SK. Radhakrishnan AK, et al. Biores Open Access. 2012 Oct;1(5):239-46. doi: 10.1089/biores.2012.0229. Biores Open Access. 2012. PMID: 23515111 Free PMC article. - Prognostic factors in low-grade non-Hodgkin lymphomas.
Federico M, Molica S, Bellei M, Luminari S. Federico M, et al. Curr Hematol Malig Rep. 2009 Oct;4(4):202-10. doi: 10.1007/s11899-009-0027-0. Curr Hematol Malig Rep. 2009. PMID: 20425409 Review. - The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E. Naparstek E. Curr Hematol Malig Rep. 2006 Dec;1(4):220-9. doi: 10.1007/s11899-006-0003-x. Curr Hematol Malig Rep. 2006. PMID: 20425317 Review. - Clonality and phenotyping of canine lymphomas before chemotherapy and during remission using polymerase chain reaction (PCR) on lymph node cytologic smears and peripheral blood.
Thilakaratne DN, Mayer MN, MacDonald VS, Jackson ML, Trask BR, Kidney BA. Thilakaratne DN, et al. Can Vet J. 2010 Jan;51(1):79-84. Can Vet J. 2010. PMID: 20357946 Free PMC article. - Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers.
Wang MX, Wang HY, Zhao X, Srilatha N, Zheng D, Shi H, Ning J, Duff DJ, Taylor KH, Gruner BA, Caldwell CW. Wang MX, et al. Int J Clin Exp Pathol. 2010 Jan 28;3(3):265-79. Int J Clin Exp Pathol. 2010. PMID: 20224725 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials